As Canadian cannabis king Tilray Brands, Inc. (NASDAQ:TLRY) prepares to report its fiscal Q2 2026 results on Thursday, the company stands at a crossroads.
TLRY stock is moving. See the chart and price action here.
After years of regulatory stagnation, President Donald Trump signed an executive order in December to speed the rescheduling of marijuana to a Schedule III substance. However, Tilray struggles to turn a profit.
Investors will be watching the company’s Q2 earnings release closely for signs of financial hope. They will also be listening for commentary on rescheduling, tax relief and the new Tilray Medical USA subsidiary.
Read Next: What To Expect At CES 2026: Nvidia, AMD, …Full story available on Benzinga.com
